

REMARKS

1. The advisory action indicates that the June 27 amendment has been entered, and that claims 1, 4-6 and 9-12 are allowed. The sole rejected claim is 26, and that claim is now cancelled, without prejudice or disclaimer.


2. In view of the allowance of amended product claim 1 by the advisory action mailed December 5, 2007, dependent method claims 15, 17, and 21-25 should have been rejoined pursuant to MPEP 821.04.

If there is a problem with these claims, we request for a telephonic interview to determine whether they can be amended to put them in a condition for allowance.

3. We note that on page 7, last paragraph of the June 27 response, there is an unfortunate typo; we should have said "the term 'PGM2 mutant' cannot be construed so broadly as to encompass PGM1" rather than "...encompass PGM2". Our intent was clear from the previous "the specification recognizes PGM1 and PGM2 as distinct entities", but we thought we would take advantage of the instant opportunity to clarify the record, even though the point is relevant only to cancelled claim 26.

Respectfully submitted,

BROWDY AND NEIMARK, P.L.L.C.
Attorneys for Applicant

By: 

Iver P. Cooper
Reg. No. 28,005

624 Ninth Street, N.W.
Washington, D.C. 20001
Telephone: (202) 628-5197
Facsimile: (202) 737-3528
IPC:lms
G:\ipc\u-z\WHBE\Bro1\pto suppl amend.wpd